Search

• Adolescent girls of color in the legal system carry higher burdens of sexual and reproductive risk (e.g., STIs/HIV, unintended pregnancy) compared to White girls and boys and are met with fewer resources that support these risks which impact short- and long-term health and well-being. • Scholarship relies on understanding how individual and family level factors impact system-involved girls' SRH rather than considering how risky contexts, including resource needs and access challenges, contribute to SRH vulnerabilities. • System-involved adolescent girls residing in the community report higher SRH risk compared to non-system involved adolescents, and report high resource needs including education, employment, mental/physical health, and technology, and significant challenges to access such resources. • Over and above individual (abuse, substance us) and family level factors (parent monitoring), resource needs were significantly associated with girls' SRH risk while resource needs and access challenges were significantly associated with Black girls' SRH risk specifically. • Interventions, programs, and policies should expand their focus on individual and family level factors to better and, more comprehensively support girls' resource needs and access challenges in mitigating SRH vulnerabilities for system-involved adolescent girls. Girls involved in the juvenile legal system are at among the highest risk for sexual and reproductive health (SRH) challenges. Yet, few studies focus on girls or examine multiple predictors of their SRH in tandem. In addition to individual and familial-level risk factors (e.g., trauma, substance use, parental monitoring), this study also examines the influence of structural disadvantage on girls' SRH by assessing the degree to which girls' self-identified resource needs and access challenges across multiple areas (e.g., housing, employment, healthcare) predict SRH risk. Cross-sectional data collected from 269 girls involved in the legal system and their caregivers were analyzed using hierarchical regression analyses. Findings suggest that, over and above individual and familial level predictors, resource access challenges significantly predict girls' SRH, while high resource needs and access challenges predict Black girls' SRH specifically. Implications for programming, policy, and research are delineated. [ABSTRACT FROM AUTHOR]

Gene-modified T cell therapies have shown clinical efficacy in targeting cancer, with promising results in treating other diseases. However, the commercialization of these breakthrough therapies remains challenging due to the increased need for research and clinical studies. To facilitate scalable, flexible, and cost-effective solutions, we have developed the Sefia™ cell therapy manufacturing platform. This modular, automated, and functionally closed technology consists of the Sefia Select™ system for T cell magnetic isolation, expanded cell harvest, and final formulation and the Sefia expansion system, designed to activate, transduce, and expand chimeric antigen receptor (CAR) T cells. Frozen (n = 3) and fresh (n = 3) leukopaks from healthy donors were purchased from Charles River and CytoCare, respectively. They were processed using the Sefia Select™ system for magnetic CD4/CD8 isolation. Isolated T cells (1 × 108) were seeded on the Sefia expansion system, activated with T Cell TransAct reagent on day 0, transduced with CAR-LVV on day 1, and expanded using serum-independent, xeno-free Akron ImmunoCell Growth Medium (Akron ICGM™). Cell recovery, purity, viability, and phenotype were quantitated on days 0, 5, and at harvest. Further processing was performed on the Sefia Select™ system and VIA Freeze™ instrument for final product formulation and freezing. Post-thaw, CAR T cell functionality was evaluated via an in vitro killing assay. The Sefia™ cell therapy manufacturing platform can expand > 2 × 109 T cells by day 7–9, with a total fold expansion of 30.18 ± 7.6, a viability of 97.5 ± 0.01%, and a CAR-LVV transduction efficiency of 55.3 ± 0.1%. With an average cell recovery > 85%, the final product represents more than the maximum therapeutic dose needed for a patient. The Sefia™ cell therapy manufacturing platform provides an end-to-end solution for autologous CAR T cell therapy manufacturing. This modular and digitally integrated platform combines two closed systems with dedicated application software and single-use kits to automate manufacturing from starting samples (fresh or frozen apheresis) to final patient doses. [ABSTRACT FROM AUTHOR]